The Pharmacodynamics Research Of Qiangyijiangtang Capsules On Experimental Diabetes And Early Diabetic Nephrpathy Rats

Objective:1. To observe the protective effects of QJC on sugar endurance in impaired glucosetolerance mice, To explore the therapeutic effect of on pre-diabetes.2. To investigate the hypoglycemic effect of Qiangyi Jiangtang Capsule onalloxan-induced diabetic mice. And determine the best glucose-lowering dose rangeand best work time.3. To investigate the pharmacodynamic effect of Qiangyi Jiangtang Capsule on thebasis situation of early diabetic nephrology rats and delay kidney， The researchconsequence contributed to provide the basis for the clinical promotion andapplication.Methods:1. Mice were injected with alloxan55mg/kg body weight though tail vein to ind uceimpaired glucose tolerance mice, QJC was administering intragastrically for2weeks.2. Mice were injected with alloxan65mg/kg body weight though tail vein to inducediabetic animals. QJC was administering intragastrically for4weeks. During theexperiment, the effects of QJC on the blood glucose, the body weight of mice, waterand food consumption were monitored every weeks.3. Diabetic nephropathy rat models were established by injecting a singlestreptozocin(STZ) in a dose of55mg/kg for the rats intraperitoneally. QJC wasadministering intragastrically for8weeks. During the experiment, the body weight ofrats, water and food consumption were monitored every2weeks. FBG, urinarycreatinine, urea nitrogen were observed after4,8weeks. At the8th weekend, allanimals were experienced the glucose tolerance test. At the8th weekend, all animalswere killed, Serum creatinine, blood urea nitrogen contents, kidney weigh, andrelative kidney weigh were also assayed. Renal and pancreatic pathologic lesionthrough light microscopy. Results:1. QJC can significantly improve the state of impaired glucose tolerancein mice.2. The diabetic mice induced by the tail vein injection of alloxan were successfullyestablished. QJC at a dose of0.9,1.8g/kg sinnificantly reduced the non-fasting bloodglucose level.3.①The diabetic nephropathy rat model have been established successfully, Comparedwith the normal group, the level of FBG of the model group increased significantly(P＜0.01)②After2and4weeks administration, except QJC(0.45g/kg) andQJC(1.8g/kg)，other groups significantly reduced the FBG level(P＜0.05，P＜0.01),NO significant difference was found in the level of FBG between QJC(0.9g/kg)group and the Metformin group、the jinqi group(P＞0.05), after8weeks administration,compared with the model group,QJC(0.9g/kg)group and jinqi group were obviouslyreduced(P＜0.05).③Compared with the model group, after half hoursadministration,all doses of groups could obviously improve the glucose tolerance(P＜0.05,P＜0.01).④after4and8weeks administration, except QJC(1.8g/kg)，othersgroups could obviously reduce urinary volume(P＜0.05), QJC(0.9g/kg) had nodifference with the jinqi group.⑤The QJC(0.9g/kg) groups could decrease ureanitrogen (P＜0.05), the level of urine creatinine was significantly decreased(P＜0.05).⑥except QJC low dose group,the other QJC groups could decrease relative kidneyweigh(P＜0.05).⑦QJC could improve pathological change in diabetic kidney andpancreas, protect renal and pancreatic function.Conclusions:1. QJC can significantly improve the state of impaired glucose tolerancein mice.2. The diabetic mice induced by the tail vein injection of alloxan were successfullyestablished. QJC at a dose of0.9,1.8g/kg sinnificantly reduced the non-fasting bloodglucose level, and decreased the food intake, water intake.But QJC have no effect onbody weight of mice.3. QJC could reduce FBG of diabetic nephrology rats, improve glucose tolerance,reduce urine creatinine, urine creatinine, and pathological changes of diabeticnephropathy and pancreas to play a role in treating diabetes and its complications.